Search for content, post, videos

He is the new Chairman at Nykode Therapeutics

Martin Nicklasson

Martin Nicklasson has been elected new chairman of Nykode Therapeutics as the company enters a new stage of internationalization.

“I am delighted to join Nykode Therapeutics as new chairman. I am extremely impressed by the company’s technology platform and R&D pipeline, as well as the company’s outstanding achievements, including closing three landmark collaboration agreements over the past fourteen months,” says Martin Nicklasson, incoming chairman of Nykode Therapeutics. “I look very much forward to assist in continuing Nykode Therapeutics’ journey of internationalization as well as to further develop Nykode Therapeutics’ position as a leading next generation immunotherapy platform company.”

Martin Nicklasson

Martin Nicklasson (born 1955) holds a Ph.D. in Pharmaceutical Sciences from the Uppsala University, Sweden, and is a certified pharmacist of Sweden. He holds a broad managerial background in the fields of e.g. marketing and R&D.

From 2007 to end 2010, Martin Nicklasson served as President and Chief Executive Officer of Biovitrum AB and Sobi AB. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc. and was a member of the Senior Executive Committee.

He has held and holds various chairman and board member positions in biotech and biopharma companies. Currently he serves as Chairman of Zealand Pharma AS and is a board member of Basilea Pharmaceutica Ltd. Martin is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from Uppsala University.

The right time to hand over the reigns as chairman

The recent name change marks a milestone in the company’s journey of growth and transformation into a fully-fledged platform company, and that Nykode Therapeutics now enters a new stage of internationalization, including a potential US footprint expansion, the company states.

“On this background, I find it the right time to hand over the reigns as chairman and to continue as an ordinary member of the board,” says Anders Tuv, outgoing chairman of Nykode Therapeutics. “I have led the search for my successor, and I am delighted that Martin Nicklasson has accepted the role as new chairman of Nykode Therapeutics. Martin Nicklasson is a well-respected and proven chairman and board member in the biotech and biopharma sector. He brings 40 years of industry experience of operating across drug development, strategic marketing and business development, prior to being a highly successful CEO. He has a global outlook and his extensive career builds on an international set of leadership experiences with e.g. AstraZeneca and Swedish Orphan Biovitrum, where he previously held key global leadership roles.”

Photo of Martin Nicklasson: Nykode Therapeutics